The MOU is a non-binding collaboration framework with no financial details, so near-term stock impact is limited. The key catalyst remains the October 2026 Phase 2 na-SPMS readout, which will provide the next material data point for foralumab's clinical profile.
Price Chart
Executive Summary
Tiziana Life Sciences signed a non-binding MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate on a clinical trial combining intranasal foralumab with anti-CD20 therapy in RRMS patients with suboptimal responses to anti-CD20 alone. The agreement adds a new MS indication to Tiziana's pipeline but does not alter its ongoing Phase 2 na-SPMS trial, which remains blinded with results expected in October 2026. No financial terms, funding commitments, or definitive trial timelines were disclosed, making this a preliminary collaboration announcement with limited near-term stock impact.
Key Facts
- MOU signed September 16, 2026 at Riyadh Global Medical Biotechnology Summit
- Parties: Tiziana, KAIMRC (King Abdullah International Medical Research Center), and Foundation for Neurologic Diseases
- Planned trial: intranasal foralumab + anti-CD20 therapy in RRMS patients with suboptimal anti-CD20 response
- Ongoing Phase 2 na-SPMS trial remains blinded; results expected October 2026
- No financial terms, funding amounts, or definitive trial start date disclosed
- Foralumab is a fully human anti-CD3 mAb; 14 na-SPMS patients dosed in open-label EA program with improvement/stability within 6 months
Financial Impact
No financial terms disclosed; non-binding MOU with no stated funding or milestone payments
Risk Factors
- MOU is non-binding; no guarantee a definitive clinical trial agreement will be signed
- No disclosed funding or cost-sharing terms — Tiziana may need to bear trial costs
- RRMS combination trial adds pipeline breadth but does not de-risk the core na-SPMS program
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3363831 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers